Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Herpes simplex vaccine - Agenus

Drug Profile

Herpes simplex vaccine - Agenus

Alternative Names: AG-707; HerpV; rhHSP70-PC

Latest Information Update: 26 Oct 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Antigenics
  • Developer Agenus
  • Class Viral vaccines
  • Mechanism of Action CD4-positive T lymphocyte stimulants; CD8 positive T lymphocyte stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Herpes simplex virus infections

Highest Development Phases

  • Suspended Herpes simplex virus type 2 infections

Most Recent Events

  • 16 Mar 2015 Agenus has patent protection for HerpV vaccine in USA
  • 01 Jan 2015 Agenus completes a phase II trial in Herpes simplex virus infections (recurrent, adjunctive therapy) in USA (NCT01687595)
  • 26 Jun 2014 HerpV is available for licensing (\http://www.agenusbio.com/\)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top